한글목차

세계의 제약 업계용 AI 시장 규모는 2025년 38억 달러에서 2025-2030년에는 CAGR 31.7%로 추이하며, 2030년말에는 152억 달러에 달할 것으로 예측됩니다.

북미 시장은 2025년 23억 달러에서 32.9%의 CAGR로 추이하며, 2030년말에는 96억 달러에 달할 것으로 예측됩니다. 아시아태평양 시장은 2025년 4억 9,630만 달러에서 36.0%의 CAGR로 추이하며, 2030년말에는 23억 달러에 달할 것으로 예측됩니다.

세계의 제약 업계용 AI 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이·예측, 각종 구분·지역별 상세 분석 등을 정리하여 전해드립니다.

목차

제1장 개요

• 시장 전망
• 조사 범위
• 시장 요약
• 시장 역학과 성장요인
• 신규 기술
• 부문 분석
• 지역 분석
• 결론

제2장 시장 개요

• 현재의 시장 개요
• 거시경제 요인 분석
• 정부의 정책과 규제
• 기술 인프라와 디지털 대응
• 세계의 무역과 공급망 역학
• 미국 관세의 영향
• Porter's Five Forces 분석
• AI가 의약품 밸류체인에 미치는 영향
• Drug Discovery와 전임상 개발 : 혁신의 가속
• 임상시험 : 보다 스마트한 설계와 시행
• 제조와 공급망 : 지능형 오퍼레이션
• 규제 업무와 컴플라이언스 : 자동화와 정확성
• 상업화와 시장 접근 : 데이터 주도의 전략
• 시판 후 조사 : 지속적 학습과 안전성 모니터링
• 사용 사례
• 사용 사례 1 : 규제 신청의 효율화를 위한 생성형 AI
• 사용 사례 2 : 합성 경로를 위한 생성형 AI 대응 R&D 어시스턴트

제3장 시장 역학

• 시장 역학
• 시장 성장 촉진요인
• 보다 신속한 Drug Discovery와 개발
• 임상시험에서 AI 도입의 증가
• 정밀의료와 AI 애플리케이션의 수요
• 시장 성장 억제요인
• 규제와 윤리상 우려
• 데이터의 과제
• 시장 기회
• 협업과 투자
• 신흥 국가에서 Drug Discovery에 대한 주목의 증가
• 분자 설계에서 생성형 AI의 진보

제4장 규제 상황

• 개요
• 미국의 규제 시나리오
• 유럽의 규제 시나리오
• 일본의 규제 시나리오
• 중국의 규제 시나리오
• 기타

제5장 새로운 동향과 파이프라인 분석

• 새로운 동향
• 제약 업계용 생성형 AI
• 연합 학습
• 자연언어처리
• 적대적 생성 네트워크
• 파이프라인 분석
• 요약
• 특허 분석
• 조사 결과

제6장 시장 부문 분석

• 세분화 내역
• 시장 내역 : 제품 유형별
• 요약
• 소프트웨어
• 서비스
• 시장 내역 : 용도별
• 요약
• Drug Discovery와 개발
• 임상시험
• 맞춤형 의료
• 기타
• 지역적 내역
• 시장 내역 : 지역별
• 요약
• 북미
• 유럽
• 아시아태평양
• 세계의 기타 지역

제7장 경쟁 정보

• 요약
• 경쟁 분석
• 전략 분석
• 투자 상황

제8장 제약 업계용 AI 시장에서의 지속가능성 : ESG의 관점

• ESG : 서론
• 지속가능성의 동향과 구상
• ESG 리스크 평가
• BCC에 의한 결론

제9장 부록

• 조사 방법
• 전시
• 약어
• 기업 개요
• AICURE
• ATOMWISE INC.
• BENEVOLENTAI
• GOOGLE DEEPMIND
• HEALX
• IKTOS
• INSILICO MEDICINE
• INVENIAI LLC.
• NVIDIA CORP.
• PATHAI INC.
• RECURSION
• SCHRODINGER INC.
• SYRENCLOUD INC.
• TEMPUS AI INC.
• XTALPI INC.
• 신규 스타트업 기업/시장 디스럽터

영문목차

The global market for artificial intelligence (AI) in pharmaceuticals is estimated to grow from $3.8 billion in 2025 to reach $15.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 31.7% from 2025 through 2030.

The North American market for AI in pharmaceuticals is estimated to grow from $2.3 billion in 2025 to reach $9.6 billion by the end of 2030, at a CAGR of 32.9% from 2025 through 2030.

The Asia-Pacific market for AI in pharmaceuticals is estimated to grow from $496.3 million in 2025 to reach $2.3 billion by the end of 2030, at a CAGR of 36.0% from 2025 through 2030.

Report Scope

This report on the global market for AI in pharmaceuticals explores market dynamics and trends, and analyzes technological developments, software performance, clinical trials, new product approvals and emerging technologies. The report also includes profiles of leading companies and their strategies.

The report explores how AI is transforming the pharmaceutical industry through enhanced diagnostic capabilities, early disease detection, clinical trial optimization, drug discovery and personalized treatment planning. It also examines AI disruption across industry verticals and value chain stages, while presenting market spending patterns, investment forecasts, R&D expenditures and venture capital funding. The report segments the market by product type, application and region. Types include software and services. Applications include drug discovery and development, clinical trials, personalized medicines and others. The four regions covered are North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data has been provided for 2024 as the base year, with forecasts for 2025 through 2030.

Report Includes

• 27 data tables and 62 additional tables
• An analysis of the global markets for artificial intelligence (AI) in the pharmaceuticals industry
• Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
• Estimates of the market's size and revenue growth prospects, accompanied by a market share analysis by product type, application and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
• Insights derived from Porter's Five Forces model, as well as a global supply chain analysis
• Case studies on AI implementation to streamline processes across drug discovery and development, manufacturing, quality control and patient care
• A relevant patent analysis, featuring key granted and published patents
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Google DeepMind, Atomwise Inc., Insilico Medicine, Recursion Pharmaceuticals and Nvidia Corp.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Current Market Overview
• Macroeconomic Factors Analysis
• Government Policy and Regulation
• Technological Infrastructure and Digital Readiness
• Global Trade and Supply Chain Dynamics
• Impact of U.S. Tariffs
• Porter's Five Forces Analysis
• Potential for New Entrants (Moderate to High)
• Bargaining Power of Suppliers (Low to Moderate)
• Bargaining Power of Buyers (High)
• Threat of Substitute Products or Services (Low to Moderate)
• Industry Level of Competitiveness (High)
• AI's Impact on the Pharmaceutical Value Chain
• Drug Discovery and Preclinical Development: Accelerated Innovation
• Clinical Trials: Smarter Design and Execution
• Manufacturing and Supply Chain: Intelligent Operations
• Regulatory Affairs and Compliance: Automation and Accuracy
• Commercialization and Market Access: Data-Driven Strategies
• Post-Market Surveillance: Continuous Learning and Safety Monitoring
• Use Cases
• Use Case 1: Generative AI for Efficiency in Regulatory Submissions
• Use Case 2: Generative AI-Enabled R&D Assistant for Synthesis Routes

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Faster Drug Discovery and Development
• Increasing Adoption of AI in Clinical Trials
• Demand for Precision Medicine and AI Applications
• Market Restraints
• Regulatory and Ethical Concerns
• Data Challenges
• Market Opportunities
• Collaborations and Investments
• Increased Focus on Drug Discovery in Emerging Nations
• Advances of Generative AI in Molecular Design

Chapter 4 Regulatory Landscape

• Overview
• Regulatory Scenario in the U.S.
• Regulatory Scenario in Europe
• Regulatory Scenario in Japan
• Regulatory Scenario in China
• Other Countries

Chapter 5 Emerging Trends and Pipeline Analysis

• Emerging Trends
• Generative AI in Pharma
• Federated Learning
• Natural Language Processing
• Generative Adversarial Networks
• Pipeline Analysis
• Takeaways
• Patent Analysis
• Findings

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Market Breakdown, by Product Type
• Takeaways
• Software
• Services
• Market Breakdown, by Application
• Takeaways
• Drug Discovery and Development
• Clinical Trials
• Personalized Medicine
• Other Applications
• Geographic Breakdown
• Market Breakdown, by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 7 Competitive Intelligence

• Takeaways
• Competitive Analysis
• Strategic Analysis
• Investment Landscape

Chapter 8 Sustainability in AI in the Pharmaceutical Industry: ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives
• ESG Risk Ratings
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• AICURE
• ATOMWISE INC.
• BENEVOLENTAI
• GOOGLE DEEPMIND
• HEALX
• IKTOS
• INSILICO MEDICINE
• INVENIAI LLC.
• NVIDIA CORP.
• PATHAI INC.
• RECURSION
• SCHRODINGER INC.
• SYRENCLOUD INC.
• TEMPUS AI INC.
• XTALPI INC.
• Emerging Start-ups/Market Disruptors